Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over period, even as revenues growth remained stagnant. The company’ stock jumped over 4% during pre-market hours.
Adjusted net profit for the second quarter came in at 12 cents per share, which was higher than the Wall Street estimate of 7 cents per share.
Revenues edged down almost 1% from last year and came in at $5.37 billion. This missed the analysts’ projection of $5.41 billion.
In the Retail Pharmacy segment, revenues edged down 1.6% hurt by store closures, even though same-store sales modestly increased 0.4%. Pharmacy sales have been negatively impacted by new generic introductions.
Front-end same-store sales, excluding cigarettes and tobacco products, decreased 0.6% year-over-year.
Outlook
Looking ahead, the company expects net sales to be in the range of $21.5 billion to $21.9 billion in fiscal 2020 and annual same-store sales growth in the range of 0-1%. Adjusted EPS is expected to be between $0.00 and $0.56.
RAD stock has declined 70% in the last one year, and 52% in the year-to-date period. The company’s inability to stop its stock from free fall culminated in CEO John Standley stepping down from the top post last month.
The newly appointed CEO Heyward Donigan has vast experience in the healthcare industry and is on Fortune’s watch list of executives who have the potential to become the world’s most powerful women.
Following failed merger bids with Walgreens (NASDAQ: WBA) and more recently Albertsons, the company is now looking up at the new CEO to save the sinking ship. The stock has slightly recovered since the appointment of Donigan.
Donigan said in a statement after the earnings announcement, “Our Adjusted EBITDA results exceeded our plan driven by prescription count growth and strong expense control. This gives us important momentum for our future, and I look forward to working closely with our team to deliver a solid finish to our fiscal year and position Rite Aid as an innovative leader in our industry.”
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
Comments
Comments are closed.